MedPath
FDA Approval

Xofigo

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Effective Date
December 10, 2019
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Radium Ra 223 dichloride(30 uCi in 1 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Institutt For Energiteknikk

Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc.

518771688

Cardinal Health 414, LLC

Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc.

079955366

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Xofigo

Product Details

NDC Product Code
50419-208
Application Number
NDA203971
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
May 24, 2017
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
Code: RJ00KV3VTGClass: ACTIBQuantity: 30 uCi in 1 mL
SODIUM CITRATE, UNSPECIFIED FORMInactive
Code: 1Q73Q2JULRClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath